bims-microg Biomed News
on Microglia in health and disease
Issue of 2026–11–22
thirteen papers selected by
Marcus Karlstetter, Universität zu Köln



  1. Nat Genet. 2026 Nov 17.
      Mounting evidence implicates microglia in neurodegeneration, but linking disease-associated genetic variants to target genes and cellular phenotypes is hindered by the inaccessibility of these cells. We differentiated 261 human induced pluripotent stem cell lines into microglia-like (iMGL) cells in pools with phenotypic (differentiation, phagocytosis and migration) and single-cell transcriptomic readouts. Burden analysis of deleterious variants detected 36 genes influencing microglial phenotypes. Expression quantitative trait locus (eQTL) analysis identified 7,121 eQTL-associated genes and 79 colocalizations across four neurodegenerative disease genome-wide association studies, half of which had limited prior evidence of causality. Integration of eQTL and phenotypic associations highlighted the role of disease-relevant variants, including LRRK2 and TREM2 acting through microglial phagocytosis. A coupled CRISPR screen identified a role for TREM2 in phagocytosis and highlighted the importance of cell type in the directionality of phenotypic effects. By contextualizing variant effects within iMGLs in different inflammatory states, we provide a comprehensive framework for interpreting the function of risk loci in neurodegenerative disorders.
    DOI:  https://doi.org/10.1038/s41588-026-02843-0
  2. Nat Neurosci. 2026 Nov 17.
      Experience-dependent changes in myelination are important for motor learning, with newly generated oligodendrocytes contributing to the formation of new myelin. However, motor memories decay over time and the underlying mechanisms remain largely unexplored. Here we show that motor memory decay is linked to changes in memory-associated myelin sheaths resulting from microglial phagocytosis in mouse brain. Mechanistically, reduced activity of motor memory engram cells lowers oligodendrocyte expression of the 'don't eat me' signal from Cluster of differentiation 47 (CD47), facilitating microglial phagocytosis and driving myelin loss. Knockout of CD47 from motor memory-associated oligodendrocytes increased microglial phagocytosis of myelin sheaths and accelerated the decay of motor memory, whereas overexpression of CD47 showed opposite results. Moreover, microglia phagocytose myelin sheaths and synapses independently. Our findings reveal that microglial phagocytosis of motor memory-associated myelin sheaths leads to the decay of motor memory. Since various types of memory require myelination in the brain, this mechanism may contribute to the decay of other memory types.
    DOI:  https://doi.org/10.1038/s41593-026-02505-8
  3. Cell Rep Med. 2026 Nov 20. pii: S2666-3791(26)00596-3. [Epub ahead of print] 103179
      The NLR family pyrin domain containing protein 3 (NLRP3) inflammasome orchestrates neuroinflammation, but its role in traumatic brain injury (TBI) and the therapeutic value of pharmacological inhibition remain incompletely defined. Using Nlrp3-deficient mice and two novel orally bioavailable selective antagonists (NP3-253 and NP3-361), we investigate NLRP3-dependent mechanisms of post-traumatic neuroinflammation and functional recovery. After controlled cortical impact, NLRP3 inflammasome components, pro-inflammatory genes, and mediators are robustly upregulated during the first post-injury week. Genetic Nlrp3 deletion and post-TBI NP3-253 treatment preserve microglial architecture and reduce aggregation and redistribution of the inflammasome adaptor apoptosis-associated speck-like protein containing a CARD (ASC), while post-TBI NP3-253 and NP3-361 therapeutically accelerate neurological recovery during treatment. Longitudinal intravital imaging shows that pre-TBI NLRP3 inhibition with NP3-361 constrains post-traumatic microglial activation in vivo. These findings establish NLRP3 as a driver of post-traumatic microglial morphodynamics and support selective NLRP3 inhibition as a promising strategy to improve neurological outcomes after TBI.
    Keywords:  ASC; NLRP3; NP3-253; NP3-361; controlled cortical impact; inflammasome; microglia; neuroinflammation; neurological recovery; traumatic brain injury
    DOI:  https://doi.org/10.1016/j.xcrm.2026.103179
  4. J Neuroinflammation. 2026 Aug 21. pii: 371. [Epub ahead of print]23(1):
       BACKGROUND: Acute disruption of cerebral blood flow rapidly induces neuronal injury and perturbs immune homeostasis within the central nervous system. As the primary immune regulators in the post-stroke brain, microglia orchestrate inflammatory responses and tissue repair. Enhancing their efferocytic capacity to clear apoptotic cells has thus emerged as a promising neuroprotective strategy. G protein-coupled receptor 84 (GPR84), which is predominantly expressed in innate immune cells, has been implicated in inflammatory responses; however, its role in cerebral ischemia remains poorly elucidated. This study investigates the clinical relevance of GPR84 in stroke and evaluates its therapeutic potential in experimental stroke models.
    METHODS AND RESULTS: ELISA analysis revealed a positive correlation between elevated peripheral blood GPR84 levels and NIHSS scores in patients with acute ischemic stroke. Integrated bioinformatics data, combined with Western blot and immunofluorescence assays, demonstrated upregulated GPR84 expression in microglia within the ischemic hemisphere. Besides, GPR84 levels in mouse peripheral blood exhibited parallel temporal dynamics with brain tissue levels throughout the first week post-transient middle cerebral artery occlusion (tMCAO). In vivo, GPR84 knockdown enhanced microglial efferocytosis, attenuated neuroinflammation, and improved short-term neurological outcomes after tMCAO. In vitro experiments using immunofluorescence and flow cytometry confirmed that GPR84 knockdown or treatment with the specific inhibitor GLPG1205 (10 µM) enhanced the efferocytosis capacity and induced a shift toward an anti-inflammatory phenotype in microglia subjected to OGD/R, which was associated with the activation of STAT6 signaling. Furthermore, administration of GLPG1205 (30 mg/kg/day) alleviated neurological deficits in tMCAO mice.
    CONCLUSION: GPR84 in microglia plays a critical role in the immune responses after ischemic stroke. GPR84 knockdown attenuated post-stroke brain injury by enhancing microglial efferocytosis and suppressing neuroinflammation. Pharmacological inhibition of GPR84 with GLPG1205 likewise exhibited therapeutic potential in experimental stroke models, although further studies are warranted to optimize its dosing regimen and clarify its detailed mechanisms of action.
    Keywords:  Efferocytosis; G protein-coupled receptor 84 (GPR84); GLPG1205; Immune responses; Ischemic stroke
    DOI:  https://doi.org/10.1186/s12974-026-04002-y
  5. J Neuroinflammation. 2026 Aug 26. pii: 378. [Epub ahead of print]23(1):
       BACKGROUND: Diabetic retinopathy (DR) is a microvascular, neurodegenerative and inflammatory disorder characterised by retinal microglial activation. In this study, we used adaptive optics optical coherence tomography (AO-OCT) to assess microglia-like cell morphology and density at the inner limiting membrane (ILM) in vivo in eyes with DR and healthy controls.
    METHODS: Eleven eyes from nine patients with DR and seven eyes from seven healthy controls were examined using a prototype AO-OCT system. Volumetric images were acquired over a 4°×4° field of view at five standardised retinal locations extending from the superior vascular arcade to the parafovea. For ultrastructural reference, a retinal sample from the foveal region of a 51-year-old donor was analysed using serial block-face scanning electron microscopy (SBFSEM).
    RESULTS: Retinal microglia-like cells were consistently visualised at the ILM in all participants using single-volume AO-OCT imaging. High-resolution imaging allowed identification of distinct morphological phenotypes consistent with histological findings and SBFSEM observations. The proportion of cells with a reactive morphology was higher in eyes with DR than in controls (median 51% vs. 16%). Overall cell density did not differ significantly between groups but showed considerable interindividual variability. In contrast, a greater proportion of cells were embedded within the ILM in DR eyes compared with controls (median 90% vs. 53%). SBFSEM provided detailed ultrastructural characterisation, revealing fine processes approximately 100-400 nm in diameter extending from the soma of microglia with a reactive morphology, a feature not previously reported.
    DISCUSSION: AO-OCT enables three-dimensional, quantitative assessment of microglia-like cell morphology and distribution in healthy eyes and eyes with DR. Eyes with DR showed an increased proportion of cells with a reactive morphology and a greater proportion of cells embedded within the ILM, suggesting increased retinal immune activation. These findings support AO-OCT as a tool for investigating retinal inflammatory changes in DR and other retinal disorders.
    Keywords:  Adaptive optics optical coherence tomography; Diabetic retinopathy; Microglia; Neuroinflammation; Retinal imaging
    DOI:  https://doi.org/10.1186/s12974-026-04007-7
  6. Proc Natl Acad Sci U S A. 2026 Nov 24. 123(47): e2613902123
      Brain ischemia induces robust neuroinflammation driven by microglial activation, yet whether ischemic neurons actively reprogram microglial phenotypes to limit inflammation remains elusive. Here, we identify neuronal interleukin-34 (IL-34) as a critical immunomodulatory signal that maintains microglial homeostasis after cerebral ischemia. We demonstrate that ischemic injury augments IL-34-CSF1R signaling between neurons and microglia. Neuron-specific overexpression of Il34 (Syn1-Il34tg mice) attenuated infarct volume and neurodeficits after middle cerebral artery occlusion, whereas neuronal Il34 knockdown exacerbated brain injury. Microglial depletion abolished IL-34-mediated neuroprotection, suggesting microglia as essential effectors. Single-cell RNA sequencing revealed that neuronal IL-34 preserved homeostatic microglial signatures (P2ry12, Cx3cr1, Tgfbr1), while suppressing inflammatory activities (Il1b, Tnf, Cxcl2) through upregulation of the transcription factor MEF2C. Mechanistically, IL-34 activated TGF-β signaling in microglia and inhibition of TGF-β signaling abolished the protective effects of IL-34, whereas microglia-specific Mef2c overexpression rescued neuroprotection despite TGF-β blockade. Thus, ischemic neurons deploy IL-34 to orchestrate the immunoregulatory activity of microglia via the TGF-β-MEF2C axis, representing a previously unrecognized endogenous mechanism counteracting neuroinflammation. Our study reveals neuronal IL-34 as a potential therapeutic target for ischemic stroke.
    Keywords:  IL-34; ischemic stroke; microglia; neuroimmune crosstalk; neuroinflammation
    DOI:  https://doi.org/10.1073/pnas.2613902123
  7. Proc Natl Acad Sci U S A. 2026 Nov 24. 123(47): e2625362123
      Neuroinflammation is a hallmark of Alzheimer's disease (AD), yet the molecular mechanisms linking microglial dysfunction to amyloid-β (Aβ) pathology remain incompletely understood. Here, we identify galectin-3 (Gal3) as a regulator of plaque-associated microglial responses, linking Aβ aggregation, lysosomal function, and neuritic pathology. Using postmortem brain tissue from AD patients, we found that Gal3+ microglia preferentially associate with cored plaques and correlate with increased LAMP1+ dystrophic neurites. Gal3 was also detected in microglial lysosomal compartments, extramicroglial dystrophic structures, and in association with extracellular amyloid fibrils, suggesting roles in both intracellular and extracellular Aβ processing. In APP mice, Gal3 deficiency reduced plaque burden and neuritic dystrophy, increased plaque compaction, and enhanced TREM2 coverage around amyloid plaques. Mechanistically, in vitro microglial experiments showed that Gal3 modulates Aβ uptake and lysosomal processing, whereas lysosomal dysfunction promoted the accumulation of fibrillar Aβ from initially monomeric species, particularly in Gal3-deficient cells. Cell-free assays demonstrated that Gal3 preferentially binds fibrillar Aβ, inhibits secondary nucleation, and alters fibril morphology, while Gal3-modified fibrillar Aβ reduces N2a neuronal cell number. Finally, in silico structural analyses identified candidate Gal3 interactors enriched in leucine-rich-repeat and immunoglobulin-like proteins, supporting a role for this lectin in immune receptor regulation. Complementary in vivo transcriptomic profiling showed that Gal3 deletion suppresses type I interferon and microglial neurodegenerative transcriptional signatures. Together, these findings position Gal3 at the interface between Aβ remodeling, lysosomal homeostasis, and plaque-associated microglial responses in AD.
    Keywords:  Alzheimer’s disease; amyloid-β; galectin-3; microglia; neuroinflammation
    DOI:  https://doi.org/10.1073/pnas.2625362123
  8. Proc Natl Acad Sci U S A. 2026 Nov 24. 123(47): e2620309123
      In living tissues, branched cells must efficiently cover territories to perform essential functions ranging from neural signaling to immune surveillance. However, how cells collectively establish and optimize tissue-scale coverage without global regulation remains poorly understood. Here, we develop a biophysical theory of interacting branched cells and show that coupling their growth to neighbor repulsion drives efficient tissue tiling with minimal territorial overlap. Strikingly, our model predicts that the same local mechanism progressively suppresses long-range density fluctuations during development, driving the system toward a large-scale order called hyperuniformity. We confirm these theoretical predictions on microglial patterning in the developing retina and show that in perturbation experiments with limited arbor growth, both tiling and fluctuation suppression are disrupted. Our results reveal that two seemingly distinct features of tissue organization, efficient space-filling and large-scale order, share a single dynamical origin, suggesting a general principle for robust tissue patterning.
    Keywords:  branching morphogenesis; hyperuniformity; space-filling; tiling; tissue patterning
    DOI:  https://doi.org/10.1073/pnas.2620309123
  9. EMBO J. 2026 Nov 15.
      CD22, an inhibitory receptor canonically expressed in B cells, is also present in microglia of the murine central nervous system. In the human brain, CD22 was predominantly found in oligodendrocytes, but also in a subset of brain-resident myeloid cells from patients with Alzheimer's disease, while it is also expressed in peripheral monocytes and differentiated THP-1 cells. CD22 has been implicated as a negative regulator of microglial phagocytosis. Here, we demonstrate that genetic ablation of CD22 in APPPS1 transgenic mice, a widely used murine model of Alzheimer's disease-like pathology, attenuates amyloid-β pathology and protects parvalbumin-positive interneurons in an age-dependent manner. Mechanistically, microglia and differentiated THP-1 cells lacking CD22 exhibit enhanced activation and phagocytosis following stimulation of the pattern-recognition receptor CLEC7A, mediated by increased SYK signaling. Conversely, activation of CD22 with the agonistic antibody epratuzumab suppresses activation of differentiated THP-1 cells. Our findings identify a CLEC7A-CD22-SYK signaling axis in both human and murine myeloid cells, in which CD22 functions as an inhibitory regulator of CLEC7A-mediated cell activation.
    DOI:  https://doi.org/10.1038/s44318-026-00961-3
  10. Neurotherapeutics. 2026 Nov 20. pii: S1878-7479(26)00294-1. [Epub ahead of print]24(1): e01124
      Major depressive disorder (MDD) is a leading cause of disability, yet current antidepressants are limited by treatment resistance and delayed onset. Neuroimmune inflammation and aberrant synaptic pruning are core pathological drivers, but targeted therapeutics remain scarce. Hydroxycarboxylic acid receptor 2 (HCAR2), a microglia-enriched GPCR and the target of niacin, has shown anti-inflammatory potential, but its role in depression is unknown. Using a chronic unpredictable mild stress mouse model with bidirectional HCAR2 manipulation, we found that chronic stress impaired hippocampal HCAR2 signaling. Niacin robustly alleviated depressive-like behaviors, whereas HCAR2 knockout markedly attenuated these effects and exacerbated stress vulnerability. Mechanistically, HCAR2 activation suppressed hippocampal neuroinflammation and microglial NLRP3 inflammasome activation via a non-canonical, ARRB2-dependent endocytic pathway: activated HCAR2 internalized into microglial endosomes, bound NEK7, and blocked NLRP3 inflammasome assembly. Concurrently, HCAR2 preserved synaptic integrity by inhibiting complement C3/CR3 signaling and attenuating excessive microglial synaptic phagocytosis. In conclusion, HCAR2 acts as an endogenous protective regulator in depression via dual mechanisms: ARRB2-mediated endosomal sequestration of NEK7 to suppress NLRP3 inflammasome, and inhibition of complement-driven synaptic pruning. These findings identify HCAR2 as a promising therapeutic target and provide a rationale for repurposing niacin in MDD treatment.
    Keywords:  Depression; HCAR2; Microglia; NLRP3 inflammasome; Synaptic pruning
    DOI:  https://doi.org/10.1016/j.neurot.2026.e01124
  11. Front Immunol. 2026 ;17 1993961
      The complement system, while having protective roles in the CNS, contributes to enhanced inflammation and cognitive decline in Alzheimer's disease (AD). C1q, is required for the initiation of the classical complement cascade but also has multiple roles that are independent of the rest of the complement cascade. Previous reports showed that constitutive global deletion of C1q reduces glial activity and attenuates neuronal loss in AD mouse models with no effect on plaque load. In a separate study young adult deletion of C1q specifically in microglia resulted in improved spatial memory performance in the more aggressive Arctic (Arc) AD mouse model again without changes in plaque accumulation. Here we used the Arc model containing floxed C1qa gene with or without RosaCreERT2 to determine if there were benefits when C1q was deleted globally in adulthood before robust amyloid accumulation or after substantial amyloid plaque accumulation vs C1q-sufficient Arc. Mice were treated with tamoxifen at either 11-wks or 20-wks of age to induce global C1q deletion. Spatial memory was tested prior to collecting brains at 10m of age. Brain sections were stained for C3/GFAP and C5aR1/Iba1 as a measure of glial activation. Superresolution microscopy was utilized to assess synaptic density of Vglut1-Psd95 synapses while confocal microscopy was used to quantify the engulfment of Vglut1 by microglia and amyloid by microglia and astrocytes. In summary, young adult global deletion of C1q in a mouse model of amyloidosis results in improved cognitive function, decreased synaptic pruning, reduced amyloid plaque accumulation and reduced astrocytic C3 expression, whereas deletion of C1q after substantial plaque deposition shows reduced C3 expression but only slight nonsignificant rescue of synaptic density, no change in amyloid accumulation and no improvement in cognitive function relative to the C1q-sufficient Arc at 10 mo of age. These findings support the role of C1q in synapse engulfment and astrocyte C3 induction and are also consistent with the hypothesis that peripheral C1q can contribute to amyloid plaque load, either directly or by modulating peripheral inflammation. The results also suggest a limited effective treatment window for targeting C1q for preservation of cognitive function.
    Keywords:  Alzheimer’s disease; C1q; amyloid; astrocytes; cognition; complement; microglia; synaptic density
    DOI:  https://doi.org/10.3389/fimmu.2026.1993961
  12. Glia. 2027 Jan;pii: e70277. [Epub ahead of print]75(1):
      Microglial M1 polarization-induced neuroinflammation drives spinal cord injury (SCI) secondary injury and progression; targeting this process effectively mitigates SCI damage and impedes disease advancement. As a molecular scaffold, tribbles pseudokinase 3 (TRIB3) engages diverse regulators to mediate downstream gene transcription and protein stability, coordinating neurological disease-associated cellular processes. GEO analysis confirmed significant TRIB3 upregulation in the T10 spinal cord of SCI rats (log2FC > 2, p < 0.001). A moderate SCI model was established in C57BL/6 mice via T10 vertebral impact. TRIB3 was upregulated in injured spinal cord tissues of C57BL/6 mice, with specific upregulation in microglia. Lentivirus-mediated TRIB3 knockdown restored motor function, ameliorated tissue injury, enhanced neuronal survival, reduced M1 polarization, and promoted M2 polarization. In vitro, TRIB3 was upregulated in LPS/IFN-γ-induced M1 microglia but downregulated in IL-4-induced M2 microglia. TRIB3 knockdown suppressed M1 polarization (decreased iNOS, CD16, CD86, TNF-α, IL-6), while its overexpression inhibited M2 polarization (decreased Arg-1, CD206, IL-10). Mechanistically, GST pull-down and co-immunoprecipitation assays revealed that TRIB3 directly interacts with transcription factor CCAAT enhancer binding protein beta (CEBPB) and suppresses its ubiquitination, thereby stabilizing the CEBPB protein. This stabilized CEBPB in turn binds to the promoter of the protein tyrosine phosphatase receptor type O (PTPRO) promoter and drives its transcription. Collectively, these findings demonstrate that TRIB3 promotes M1 polarization and accelerates SCI pathogenesis via the CEBPB/PTPRO axis, highlighting this pathway as a promising therapeutic target for SCI intervention.
    Keywords:  CEBPB; PTPRO; TRIB3; microglial cell; spinal cord injury (SCI); ubiquitination
    DOI:  https://doi.org/10.1002/glia.70277
  13. Exp Cell Res. 2026 Nov 20. pii: S0014-4827(26)00354-X. [Epub ahead of print] 115237
      Diabetic encephalopathy (DE) is a common central nervous system complication of diabetes, characterized by cognitive decline and neuroinflammation. Mitochondrial dysfunction is closely implicated in DE pathogenesis, yet the underlying mechanisms remain poorly understood. Here, by intersecting published diabetes-associated microglial genes with mitophagy-related genes, we identified SLC15A3, which was highly expressed in microglia. SLC15A3 overexpression induced microglial activation, oxidative stress, and neuroinflammation, manifested by increased IBA-1 expression, enhanced migration, elevated ROS and MDA levels, and upregulated pro-inflammatory cytokines. Conversely, SLC15A3 knockdown effectively reversed high glucose (HG)-induced microglial oxidative stress and inflammatory activation. Mechanistically, Nucleotide-binding Oligomerization Domain-containing protein 2 (NOD2) was identified as a candidate interacting protein of SLC15A3. SLC15A3 upregulated NOD2 expression to activate the downstream JNK/DRP1 signaling axis, thereby aggravating mitochondrial lipid peroxidation, reducing mitochondrial membrane potential, and triggering aberrant PINK1/Parkin-dependent mitophagy dysregulation. Notably, JNK knockdown significantly rescued SLC15A3-induced mitochondrial dysfunction. Importantly, this SLC15A3-NOD2 regulatory axis was further validated in primary murine microglia. In a microglia-endothelial co-culture blood-brain barrier (BBB) model, SLC15A3 silencing alleviated HG-evoked BBB permeability damage and restored the expression of tight junction proteins. In vivo hippocampal knockdown of SLC15A3 or NOD2 mitigated BBB disruption, reduced neuronal apoptosis, and partially attenuated cognitive deficits in DE mice. Collectively, this study demonstrates that SLC15A3 facilitated mitochondrial lipid peroxidation and mitophagy dysregulation via a NOD2-dependent JNK/DRP1 pathway, thereby accelerating BBB injury and DE progression. SLC15A3 represents a potential therapeutic target for diabetic cognitive complications.
    Keywords:  Diabetic encephalopathy; JNK/DRP1 signaling pathway; Microglia; Mitochondrial lipid peroxidation; SLC15A3
    DOI:  https://doi.org/10.1016/j.yexcr.2026.115237